Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of OPC-61815 on QT/QTc Interval in Healthy Male Subjects
NCT03510663Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tolvaptan in heart failure (HF) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram at 24 hours. Started May 2018; status: completed.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03510663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510663.